Abstracts tagged "Osteoarthritis"

Abstract Number: 1730 • ACR Convergence 2024
Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Daniel Portnoy¹, Matthieu J Piola², Luke Hao², Robert Winchester², Adam Mor² and Yevgeniya Gartshteyn³, ¹Columbia University Irving Medical Center, New Yok, NY, ²Columbia University Irving Medical Center, New York, NY, ³Columbia University Irving School of Medicine, New York, NY
Background/Purpose: Inflammatory arthritis is one of the most common immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs). We hypothesized that T cells present…
Abstract Number: 2092 • ACR Convergence 2024
Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial
Chenchen Wang¹, Timothy McAlindon², Meghan Short¹, Mei Chung³, Ye Chen¹, Albert Tai¹ and Honorine Ward¹, ¹Tufts Medical Center, Boston, MA, ²University of Massachusets, Worchester, MA, ³Tufts Medical Center, Brighton, MA
Background/Purpose: Previous studies show that Tai Chi achieves clinical improvement for osteoarthritis (OA) through multiple pathways. There is evidence for interaction of the gut microbiota…
Abstract Number: 2108 • ACR Convergence 2024
A Pilot Randomized Controlled Trial for Hand Osteoarthritis
Grace Lo¹, Kimberly Staines², Michael Strayhorn³, Katherine Tse⁴, Gerald Virtanen², Laura Welsh⁴, Monica Seu⁴, Eugene Gersh⁴, Peter Richardson³, Ida Haugen⁵ and Jonathan Samuels⁶, ¹Baylor College of Medicine / MEDVAMC, Houston, TX, ²Michael E. DeBakey VA Medical Center, Houston, ³Baylor College of Medicine, Houston, ⁴NYU Langone Health, new york, NY, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶NYU Langone, Rye Brook, NY
Background/Purpose: Because of the altered joint biomechanics seen in nodal hand OA, there may be a role for traction using non-invasive finger traps in this…
Abstract Number: 0026 • ACR Convergence 2024
Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin
Michael Newton¹, Aanya Mohan², Tareq Hanna³, Dana Orange⁴, John Varga² and Tristan Maerz², ¹University of Michigan, South Lyon, MI, ²University of Michigan, Ann Arbor, MI, ³Wayne State University, Detroit, MI, ⁴The Rockefeller University, New York, NY
Background/Purpose: Synovial fibrosis is a hallmark of osteoarthritis (OA) and a clinical correlate to joint pain. Fibrosis of skin, lungs and other organs is the…
Abstract Number: 0794 • ACR Convergence 2024
Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Shreena Kamlesh Gandhi¹, Sofia Pedro², Brian Walitt³, Winfried Häuser⁴, Robert Katz⁵ and Kaleb Michaud⁶, ¹KU School of Medicine, Wichita, Wichita, KS, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³NIH, Bethesda, MD, ⁴Klinikum Saarbrücken Germany, Munich, Germany, ⁵Rush University Medical Center, Chicago, IL, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disability benefits are crucial for individuals unable to work due to debilitating medical conditions, commonly facilitated through programs like Social Security Disability Insurance (SSD)…
Abstract Number: 1177 • ACR Convergence 2024
Supporting Implementation of Group Physical Therapy for Knee Osteoarthritis: Results of a Multisite Implementation Trial
Kelli Allen¹, Sara Webb², Livia Anderson², lauren Abbate³, Lindsay Ballengee⁴, Cynthia Coffman², Connor Drake⁵, Graham Cummin⁵, Helen Hoenig⁵, Jaime Hughes⁶, Nina Sperber⁵, Matthew Tucker⁵, Amy Webster⁵, Leah Zullig⁵, Courtney Van Houtven⁵ and Susan Hastings⁵, ¹University of North Carolina, Durham, NC, ²Durham VA Healthcare System, Durham, NC, ³VA Eastern Colorado, Denver, CO, ⁴Duke University, Durham, NC, ⁵Durham VA Healthcare System, Durham, ⁶Wake Forest University, Winston Salem
Background/Purpose: Prior research has shown that compared to individual PT, group-based physical therapy (Group PT) yields equivalent or greater improvement in outcomes for patients with…
Abstract Number: 1197 • ACR Convergence 2024
Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
François Rannou¹, Christelle Nguyen¹, Camille Daste¹, Quentin Kirren¹, marie-martine Lefevre-Colau¹, Odile Launay², Lucille Desallais³, Edita Dolimier³, René Azoulai³, Jean-Pierre Salles³ and Jean-François Zagury⁴, ¹AP-HP. Centre-Université Paris Cité, Hôpital Cochin, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Paris, Ile-de-France, France, ²Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France, ³Peptinov, Paris, Ile-de-France, France, ⁴Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Chaire de Bioinformatique, Conservatoire National des Arts et Métiers, Paris, Ile-de-France, France
Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…
Abstract Number: 1234 • ACR Convergence 2024
Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration
Nadine Henderson¹, Claud Theakston¹, Sulayman Chowhury¹, David Mott¹, Chris Skedgel¹, rita Freitas², Stefan Ivanicius³, Gudula Petersen³, Samantha Schofield³, Angie Botto-van Bemden⁴, Mickaël Hiligsmann⁵, Ricardo larrainzar⁶, Deborah Marshall⁷, Tommi Tervonen⁸ and David Walsh⁹, ¹Office of Health Economics, London, United Kingdom, ²Grünenthal GmbH, Aachen, Germany, ³Grunenthal GmbH, Aachen, Germany, ⁴Musculosketal Research International, Miami, FL, ⁵Maastricht University, Maastricht, Netherlands, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷University of Calgary, Calgary, AB, Canada, ⁸Kielo Research, Zug, Switzerland, ⁹University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Knee osteoarthritis (KOA) is a leading global cause of disability and chronic pain (Cross et al., 2014). It is well established that KOA affects…
Abstract Number: 1880 • ACR Convergence 2024
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
Rafael Sanchez-Dopazo,¹, malay rathod², Ashwinikumar Shandilya³, Janmay Vala⁴, Eva Kalra⁵, Tapan Giri⁶, Saif Syed⁷, Mohit Lakkimsetti⁸, Juhi Patel⁹, VISHRANT AMIN¹⁰ and Hardik Desai¹¹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Monmouth Medical Center, Rutgers University, Ewing, NJ, ³Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Trident Medical Cente, Charleston, SC, ⁶BJ Medical College, Pune, Pune, Maharashtra, India, ⁷Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁸Mamata Medical College,Khammam, Khammam, Telangana, India, ⁹GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹¹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…
Abstract Number: 2093 • ACR Convergence 2024
Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial
Christopher Swearingen¹, Yusuf Yazici², Jeyanesh Tambiah³ and Philip G Conaghan⁴, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²NYU Grossman School of Medicine, La Jolla, CA, ³Biosplice Therapeutics Inc., San Diego, CA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways, demonstrated beneficial effects on clinical and radiographic outcomes in previous knee…
Abstract Number: 2109 • ACR Convergence 2024
Pincer Grip and Metacarpophalangeal Patterns Emerge as New Phenotypes of Hand Osteoarthritis Using a Data Driven Approach: Data from the Osteoarthritis Initiative
Grace Lo¹, Jeffrey Driban², Charles Eaton³, Mary Roberts⁴, Lena Schaefer⁵, Stacy Smith⁵, Ida Haugen⁶, Jane Cauley⁷, Alan Rathbun⁸, Alexa Meara⁹, Marc Hochberg¹⁰, Kent Kwoh¹¹, Susan Rubin¹² and Timothy McAlindon¹³, ¹Baylor College of Medicine / MEDVAMC, Houston, TX, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Brown University, Pawtucket, RI, ⁴Brown University, Providence, RI, ⁵Brigham and Women's Hospital / Harvard Medical School, Boston, MA, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Maryland School of Medicine, Baltimore, MD, ⁹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁰University of Maryland School of Medicine, Cambridge, MD, ¹¹University of Arizona, Tucson, AZ, ¹²UCSF, San Francisco, ¹³University of Massachusetts Chan Medical School, Worcester
Background/Purpose: Determination of osteoarthritis (OA) phenotypes provides a deeper understanding of the nature of the disease and progress towards precision- based intervention. Hand OA is…
Abstract Number: L04 • ACR Convergence 2023
EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
James Helliwell¹, Amanda Malone¹, Mark Kowalski², Asger Reinstrup Bihlet³, Claire Miller⁴, Alejandro Castillo Mondragon⁵, Yanqi Li⁶, Christine Dobek⁷, Vik Peck¹, Mike Wilmink⁸ and Lee Simon⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²Eupraxia Pharmaceuticals, Winchester, VA, ³NBCD A/S, Soeborg, Denmark, ⁴NBCD A/S, Copenhagen, Denmark, ⁵NBCD, Copenhagen, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷Eupraxia Pharmaceuticals, Edmonton, AB, Canada, ⁸OrthoArizona, Phoenix, AZ, ⁹SDG LLC, Cambridge, MA
Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…
Abstract Number: L05 • ACR Convergence 2023
DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis
Guoqi Cai¹, Graeme Jones², Flavia Cicuttini³, Anita Wluka³, Yuanyuan Wang³, Catherine Hill⁴, Helen Keen⁵, Benny Antony², barbara de Graaff², Michael Thompson², Tania Winzenberg², Kathy Buttigieg², Petr Otahal² and Dawn Aitken², ¹School of Public Health, Anhui Medical University, Hefei, China, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Monash University, Melbourne, Australia, ⁴The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁵Fiona Stanley Hospital, Murdoch, Australia
Background/Purpose: There is an unmet need for treatments of knee OA. Diacerein is recommended for alleviating pain in OA patients for its anti-inflammatory effect by…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0315 • ACR Convergence 2023
Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy
Tom Niessink¹, Tim Welting², Matthijs Janssen³, Cees Otto⁴ and Tim Jansen⁵, ¹University of Twente, Utrecht, Netherlands, ²MUMC+, Maastricht, Netherlands, ³Viecuri MC / Venlo, Wijgmaal, Belgium, ⁴University of Twente, Enschede, Netherlands, ⁵VieCuri MC, Venlo, Netherlands
Background/Purpose: Calcium containing crystals in osteoarthritis (OA) are of interest as they potentially stimulate the NRLP-3 inflammasome and may become treatable with novel therapeutics. Previous…

« Previous Page
1
…
7
8
9
10
11
…
63
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].